Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 5, 1996, Pages 757-763

  Mee, A S ^a   Rowley, J L ^b  

^a ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^b Lederle Laboratories   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; ENDOSCOPY; EPIGASTRIC PAIN; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS;

EID: 0029797692     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.56198000.x     Document Type: Article

References (17)

1. Nebel OT, Forbes MF, Castell DO. Symptomatic gastro-esophageal reflux: Incidence and precipitating factors. Am J Dig Dis 1976; 21: 853-6.
2. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 50-67.
3. Colin-Jones DG. Histamine-2-receptor antagonists in gastro-oesophageal reflux. Gut 1989; 30: 1305-8.
4. Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. Aliment Pharmacol Ther 1995; 9: 145-51.
5. Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux oesophagitis. Scand J Gastroenterol 1998; 23: 625-32.
6. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15 mg and 30mg of lansoprazole and 20 mg omeprazole. Gastroenterology 1994; 106: A197. (Abstract.)
7. Bruley des Varannes S, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24 hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.
8. Barradell LB, Faulds D, McTavish D, et al. Lansoprazole; A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid related disorders. Drugs 1992; 44: 225-50.
9. Gerloff J. Bioavailability of lansoprazole. Data on file. Gosport, UK: Lederle Laboratories.
10. Cederberg C, Andersson T, Skanberg I. Omeprazole pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989; 24(Suppl. 166): 33-40.
11. SAS Release 6.08. Cary, North Carolina: SAS Institute Inc.
12. Robinson M, Sahba B, Jhalas N, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25-31.
13. Havelund T, Laursen LS, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double-blind comparative trial. Br Med J 1988; 296: 89-92.
14. Castell DO, Richter JE, Robinson M, Sontag S. Large trial compares lansoprazole to omeprazole. Gastroenterology 1995; 108: A67. (Abstract.)
15. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole vs omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993; 28: 224-8.
16. Dorsch E, Jones J, Padgett C, et al. Lansoprazole heals moderate to severe reflux oesophagitis. Am J Gastroenterol 1991; 86: 1294 (Abstract).
17. Corallo J, Vicari F, Forestier S, et al. Lansoprazole in acute treatment of reflux oesophagitis. Gastroenterology 1993; 104 (4 part 2): A58. (Abstract.)